As precision medicine advances, approaches to benefit–risk must evolve beyond traditional models designed for large, repeatable populations. This webinar brings together patients, families, regulators, and industry to explore how benefit–risk is understood, weighed, and acted on in the context of highly individualized therapies. Through real-world perspectives, panelists will examine what outcomes matter most, how risk is navigated under uncertainty, and what it means to make truly informed decisions.
Building on C-Path’s February webinar on transforming drug development for precision medicines, which explored evidence generation, data strategies, and regulatory pathways, this session advanced the conversation by centering the patient voice and highlighting the shift toward more coordinated, patient-centered approaches in benefit–risk decision-making.
What We Covered:
- How traditional development models translate to personalized contexts
- Patient and family perspectives on real-world benefit–risk decisions
- How benefit–risk evolves as new therapies become available
- Opportunities for collaboration across patients, regulators, and industry
View the recording below:
